Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis

Zimmer Biomet Holdings (ZBH) is a healthcare medical device company based in Warsaw, Indiana that builds replacement joints and surgical repair hardware. Founded in 1927, the company manufactures reconstructive knee and hip implants, sports medicine soft-tissue repair tools, craniomaxillofacial devices, and bone cement. They also produce specialized thoracic fixation hardware to stabilize chests following trauma or open-heart surgery. Their core buyers are orthopedic surgeons, neurosurgeons, hospital networks, and healthcare purchasing organizations.

Zimmer Biomet is a dominant market leader, holding approximately 33% of the global knee and hip implant sector. The broader orthopedic market generates roughly $24 billion annually, with Zimmer Biomet, Stryker, DePuy Synthes, and Smith+Nephew capturing about 71% of total sales. Their lead is under persistent threat from Stryker, which captured roughly 6.5% in additional market share over the last decade by aggressively deploying its Mako robotic platform. Zimmer Biomet relies on its proprietary ROSA robotic system to defend its turf, making surgical robotics the central battleground for their business.

The company is currently executing a strategic pivot from basic implant manufacturing toward integrated digital surgery and data analytics. Generating approximately $8.2 billion in annual revenue, Zimmer Biomet is anchoring its future on the ZBEdge platform, which combines robotics, artificial intelligence, and surgical data collection. This technological transition is critical for their bottom line because hardware alone has become commoditized. Locking hospital operating rooms into their digital ecosystem is their single best lever to drive recurring revenue and preserve pricing power.